(BRAVEinMS) Bioinformatics and cell ReprogrAmming to deVElop an IN vitro platform to discover new drugs for progressive Multiple Sclerosis (BRAVEinMS) BRAVEinMS rises from the joint efforts of laboratories from five different countries in Europe and North America with the aim of merging and synergizing unique competences in order to identifying promising molecules that can counteract the progression [...]
WOMEN4HEALTH A unique cohort to study mechanisms underlying cardiometabolic disorders in Women Do you know that the leading cause of death for women is not breast or uterine cancer, but cardiometabolic diseases, which include type 2 diabetes and metabolic syndrome? Italian, national statistical data from 2018 indicates that the incidence of [...]
We are studying the gut microbiome and human genome of about 8,000 from the Dutch Microbiome Project, an ambitious project involving volunteers of the Lifelines Population Biobank. In this project we aim to investigate if and how host genome affects microbiome composition and function.
Selection with a molecUlar PanEl foR Panitunumab Efficacy in K-ras and n-ras wild type metastatic colorectal cancer. This study aims to prospectively define a molecular panel able to identify patients more likely to benefit from the use of first-line panitumumab in combination with mFOLFOX.
Sequential Combo Immuno & Target therapy (SECOMBIT) study. A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/ nivolumab) & combo target therapy (LGX818/MEK162) in patients with metastatic melanoma and BRAF mutation [...]
SeconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status. Phase II Trial. Circulating tumor DNA (Liquid Biopsy) testing, before and during treatment, is used to assess whether the status of selected tumor biomarkers evolve during tumor progression.
Dabradenib and Trametinib in circulating free DNA BRAF mutated positive melanomas: a prospective phase II study. The “liquid biopsy” used as DNA source, represents an alternative approach to identify the clinically relevant cancer mutational landscape when monitoring disease progression and treatment response.
An evaluation of the efficacy beyond progression of vemurafenib combined with cobimetinib associated with local treatment compared to second-line treatment in patients with BRAFV600 mutation-positive metastatic melanoma in focal progression with first-line combined vemurafenib and cobimetinib
Cancer progression and metastatization is a complex process in which genetic alterations were initially demonstrated to assume a significant role; however, more recent evidence point to tumor microenvironment (TME) and host's immune system as additional players in cancer progression.
Molecular-genetics testing cooperate in defining the more appropriate and effective diagnostic and therapeutic approaches for the managements of cancer patients. Molecular diagnostics project carried out thanks to an agreement with the University Hospital (AOU) of Sassari.
Personalized approaches for diagnosis and treatment of cancer. The Unit of Cancer Genetics at IRGB-CNR of Sassari is fully focused on precision medicine in oncological field, mostly based on translational research and, to a lesser extent, on basic research. In clinical practice, genomic and epigenomic profiling actually represents a crucial tool for the molecular classification of cancer patients [...]
